Scott Rooney, MD
Interventional Pain Medicine · Hoover, ALNPI 1447788047
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,110 and has fallen 90.6% since, to $104 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in AL, where the typical reported total is $4,812.
Across 102 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$573
- Abbott$477
- Nevro Corp.$298
- SPR Therapeutics, Inc$288
- Collegium Pharmaceutical, Inc.$231
- Medtronic$158
- plus $640 from 10 others
What the payments were for
- Food & beverage$2,666100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 19 | $573 |
| Abbott | 13 | $477 |
| Nevro Corp. | 7 | $298 |
| SPR Therapeutics, Inc | 15 | $288 |
| Collegium Pharmaceutical, Inc. | 13 | $231 |
| Medtronic | 3 | $158 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $126 |
| AbbVie | 6 | $100 |
| Saluda Medical Americas, Inc. | 2 | $86 |
| Almatica Pharma LLC | 4 | $71 |
| Scilex Pharmaceuticals Inc. | 4 | $69 |
| Averitas Pharma Inc. | 3 | $66 |
| Relievant Medsystems, Inc. | 1 | $51 |
| Lilly USA, LLC | 2 | $31 |
| Pfizer | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$286
- SPECTRA WAVEWRITER$253
- Omnia$215
- INTELLIS ADAPTIVESTIM$114
How this compares
$2,666 in reported general payments places this provider in the 30th percentile of 33 interventional pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 417 | $102,495 |
| BelbucaBuprenorphine Hcl | 128 | $75,208 |
| Nucynta ErTapentadol Hcl | 43 | $45,660 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 205 | $41,796 |
| Xtampza ErOxycodone Myristate | 42 | $31,297 |
| RelistorMethylnaltrexone Bromide | 12 | $28,528 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,259 | $28,260 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 850 | $21,485 |
| Lidocaine | 258 | $20,203 |
| ZtlidoLidocaine | 49 | $17,413 |
| MovantikNaloxegol Oxalate | 41 | $17,193 |
| OxycontinOxycodone Hcl | 21 | $14,251 |
| Gabapentin | 1,107 | $12,291 |
| Hysingla ErHydrocodone Bitartrate | 14 | $9,712 |
| Naloxone Hcl | 129 | $9,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er, Xtampza Er | $231 | $152,165213 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $126 | $28,52812 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $69 | $17,41349 claims |
| AbbVieLinzess | $100 | $7,14614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 33 interventional pain medicine providers in Alabama.
Other interventional pain medicine in Hoover
- Roberto ChangHoover$13K
- Thomas MartinHoover$11K
- Michael GibsonHoover$8K
- Michael KendrickBirmingham$90K
- Bradley WargoMuscle Shoals$41K
- Jacob VellaMontgomery$28K
- John IronsVestavia$22K
- Richard WebbFoley$18K
- Ryan AlmeidaBirmingham$14K
- Bradley KatzMontgomery$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.